Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
about
Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?Medication Adherence and Health Outcomes of People Living with HIV Who Are Food Insecure and Prescribed Antiretrovirals That Should Be Taken with Food.Quantification of antiretroviral drugs for HIV-1 in the male genital tract: current data, limitations and implications for laboratory analysis.Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trialGenomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers.Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infectionCurrent and Novel Inhibitors of HIV ProteaseDirect spectroscopic evidence of hyperconjugation unveils the conformational landscape of hydrazides.Organic carbamates in drug design and medicinal chemistryEffect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimenMechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport.Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant womenInfluence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.Impact of a pharmaceutical care program on clinical evolution and antiretroviral treatment adherence: a 5-year study.Experience with tenofovir disoproxil fumarate for antiretroviral therapy.Efficacy of a clinical decision-support system in an HIV practice: a randomized trial.Pharmacogenomics of CYP3A: considerations for HIV treatment.Effect of the African Traditional Medicine, Sutherlandia frutescens, on the Bioavailability of the Antiretroviral Protease Inhibitor, Atazanavir.Antiviral drug disposition and natural health products: risk of therapeutic alteration and resistance.The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.Clinical pharmacology, efficacy and safety of atazanavir: a review.Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients.Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.Ritonavir-boosted protease inhibitors in HIV therapy.Food and Drug Interactions.Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults.Plasma and Intracellular Antiretroviral Concentrations in HIV-Infected Patients under Short Cycles of Antiretroviral Therapy.Treatment outcomes among people living with HIV who are food insecure and prescribed antiretrovirals taken with food.A single centre cohort experience with a new once daily antiretroviral drug.Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1.Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients.
P2860
Q28546430-AB29584C-B775-4F0E-918E-D8C26E1F24FCQ30628813-1CC6AE4F-52A1-4EE1-9DDD-C89E4ACB8B24Q31135042-5DD04B04-36DB-4BE1-BA86-E5C55BCC5005Q33348311-0B6F2BC2-434F-4BA9-886B-842CE3E6C520Q33760652-53F0F503-CD21-44D8-88F8-C99F54D35D5FQ34404878-C59D3A10-2BB9-475F-83E0-C63AA496491AQ35127808-72854DC7-C8B1-4812-9FE5-010D5FD035BEQ35259915-D49944C0-7C81-4FA1-99D1-847E56D13608Q35314623-9BEDFE44-4D00-45E7-9F3F-90E98D7F927BQ35365543-BD47CDF0-247D-46D3-A436-F0CA41783082Q35404442-9F208F36-3EE9-4170-BD9E-FB169AB85033Q35598523-ACA22D53-C8BD-47A2-9EDD-FA7B122FD533Q35758844-306C8F10-0E33-4190-9EE1-FFF68377779BQ36303746-573F1050-C332-4309-BDF5-2F8892B16BDFQ36628549-56878199-BF7D-41E0-8E63-EE355722DE56Q36779146-1689AC37-8ECD-49D9-AF29-9E67117531C4Q36785804-60EA5EA3-4CFE-4FC1-BFDC-DD9E8DEF6168Q36803454-3F4DB427-742E-4529-9514-C92E7742F364Q37113947-4ACF184D-44FF-4791-A324-227CB6925E41Q37115824-73E1B55E-FFE0-4238-9E51-94676BF0B267Q37142078-BE907A28-1A3F-4093-A921-DA11C44A0322Q37313077-FB4A2850-FB54-4EA1-9A1B-2F8A382DF73BQ37419542-0DFD37ED-C513-4ABD-8107-F46131479CEFQ37422412-30862FC4-B2ED-4677-9332-9676B1292198Q37481442-1A0A4E37-9F45-4D8F-954E-CB22AA35F3FEQ37593100-9501B812-A817-4CD4-BDD6-FD15DF9C33A4Q37611687-D69FDE27-4E46-437F-88D9-A268B7A581F9Q37622972-A74F3787-61F9-45AD-8ECD-9FF740212CA4Q37845854-37AD758F-D320-44CE-8D86-8EEDCC8D1391Q37866298-6C843860-F188-4442-90E5-CEB28E693CD9Q37866319-ACD4E92E-66DF-4B46-90C7-F636F6AA4F07Q39162829-353AFBD5-753B-4C15-8CFD-34DD1C5D563DQ40488073-D12AF3D2-066F-4FD4-BF66-C70F341A4EBCQ40555236-164D5BEA-DE5B-4D4B-9EC2-95F82EBE97FBQ41644790-8E919918-C939-4C36-A3EA-004A1EE19471Q41747332-DAF3CAE2-8445-47BB-AC99-7432C0D72BF8Q42107646-CBD95315-10CD-4081-BC60-9EF6434191C3Q42256493-1295ED8F-3FA5-4DEF-859B-4DB41FB42161Q42956923-17A96098-D5C4-42A6-9A85-164B5CBA0F68Q43618119-547FCD44-C85D-4447-AB9B-A8D73A5F101C
P2860
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
@ast
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
@en
type
label
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
@ast
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
@en
prefLabel
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
@ast
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
@en
P2093
P1476
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
@en
P2093
Anne-Marie Taburet
Aurélie Barrail
Clotilde Le Tiec
Cécile Goujard
P304
P356
10.2165/00003088-200544100-00003
P577
2005-01-01T00:00:00Z
P6179
1030672498